Categories: News

Shockwave Medical to Participate in the Bank of America Securities 2021 Health Care Conference

SANTA CLARA, Calif., April 27, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the upcoming Bank of America Securities 2021 Health Care Conference that is being held virtually from May 10-12, 2021.

Shockwave Medical’s management is scheduled for a live Fireside Chat on Tuesday, May 11, 2021 at 3:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the “Investors” section of the company’s website at: https://ir.shockwavemedical.com.

About Shockwave Medical, Inc.

Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit www.shockwavemedical.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com 

Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com 

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago